[1]李 瑞,葛 静,周迪兰,等.5-氨基酮戊酸光动力治疗高危型人乳头状瘤病毒宫颈持续感染疗效观察[J].陕西医学杂志,2019,(7):930-932,957.
　LI Rui,GE Jing,ZHUO Dilan,et al.Observation on the efficacy and prognosis of ALA-PDT in the treatment of high-risk HPV cervical persistent infection[J].,2019,(7):930-932,957.
点击复制

5-氨基酮戊酸光动力治疗高危型人乳头状瘤病毒宫颈持续感染疗效观察
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年7期
页码:
930-932,957
栏目:
临床研究
出版日期:
2019-07-05

文章信息/Info

Title:
Observation on the efficacy and prognosis of ALA-PDT in the treatment of high-risk HPV cervical persistent infection
文章编号:
DOI:10.3969/j.issn.1000-7377.2019.07.033
作者:
李 瑞; 葛 静; 周迪兰; 王文英; 秦 琳
解放军总医院第四医学中心妇产科（北京 100048）
Author(s):
LI Rui; GE Jing; ZHUO Dilan; et al.
Department of Obstetrics and Gynecology， Fourth Medical Center of PLA General Hospital(Beijing 100048)
关键词:
高危型人乳头状瘤病毒; 宫颈; 感染; 5-氨基酮戊酸光动力疗法; 重组人干扰素α-2b阴道泡腾胶囊; 转阴率; HPV DNA负荷量
Keywords:
Key words High risk human papillomavirus; Cervix; Infection; 5- Aminolevulinic acid phtodynamic therapy; Recombinant human interferon alpha -2b vaginal effervescent capsules; Negative rate; HPV DNA load
分类号:
R711.7
文献标志码:
A
摘要:
摘 要 目的：探讨5-氨基酮戊酸光动力（ALA-PDT）疗法治疗高危型人乳头状瘤病毒（HR-HPV）宫颈持续感染的疗效及预后影响。方法：将HR-HPV宫颈持续感染且病程＞1年的86例患者作为研究对象，采用单盲随机数表法分为两组各43例，分别采用常规重组人干扰素α-2b阴道泡腾胶囊宫颈给药和ALA-PDT疗法治疗，记为重组人干扰素组和ALA-PDT组，两组治疗后均通过门诊随访3个月，观察HPV转阴效果和HPV DNA负荷量的变化情况，并统计不良反应情况。结果：两组治疗结束后均成功随访3个月，ALA-PDT组HPV转阴率62.79%（27/43）显著高于重组人干扰素组34.88%（15/43），差异有统计学意义（P＜0.05）；HC-II 定量检测显示，ALA-PDT组宫颈HPV DNA负荷量下降幅度≥90%和≥50%的比重分别为62.79%（27/43）、76.74%（33/43），明显高于重组人干扰素组34.88%（15/43）、55.81%（24/43），组间差异有统计学意义（P＜0.05）。ALA-PDT组治疗随访期间仅出现少量轻度不适症状，均可耐受。结论：ALA-PDT疗法是促进高危型HPV宫颈持续感染转阴、降低HPV DNA负荷量的有效手段，且安全性较好，对降低癌变风险和改善预后质量具有显著意义。
Abstract:
Abstract Objective：To investigate the efficacy and prognosis of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in the treatment of persistent cervical infection of high-risk human papillomavirus (HR-HPV).Methods： A total of 86 consecutive patients with HR-HPV persistent infection and 1 years' duration of treatment in our hospital from June 2016 to June 2018 were enrolled in the study. They were divided into two groups and 43 cases by single blind random number table. They were treated with routine recombinant human interferon alpha -2b vaginal effervescent capsules delivery and ALA PDT therapy，respectively，as the recombinant human interferon group and ALA PDT group，and two groups were treated through the door after treatment. Follow-up for 3 months to observe the negative effect of HPV and the change of HPV DNA load，and to count the adverse reactions.Results： The HPV negative conversion rate of ALA-PDT group was 62.79% (27/43)，which was significantly higher than that of recombinant human interferon group (34.88% (15/43)，and the difference was statistically significant (P ＜ 0.05). Quantitative detection of HC-II showed that the percentage of cervical HPV DNA load decreased by more than 90% and more than 50% in ALA-PDT group was 62.79% (27/43) and 76.74% (33/43)，respectively，which was significantly higher than that in recombinant human interferon group. The interferon group was 34.88% (15/43) and 55.81% (24/43)，with significant difference between the two groups (P＜ 0.05). During the follow-up period，only a few mild discomfort symptoms appeared in ALA-PDT group，which were tolerable.Conclusion：ALA-PDT therapy is an effective method to promote the negative transformation of high-risk HPV cervical persistent infection and reduce HPV DNA load. It is safe and has significant significance in reducing the risk of canceration and improving the quality of prognosis.

参考文献/References:

[1] 魏 英，李婷婷，邓志纬，等. 湖北十堰地区女性宫颈人乳头状瘤病毒感染与亚型分布[J]. 中国医药导报，2017，14(9)：107-110. [2] Otter S. Whitaker J.The Human Papillomavirus as a Common Pathogen in Oropharyngeal，Anal and Cervical Cancers[J].Clinical Oncology，2019，2(31)：81-90. [3] 王 林，姜明月，秦 宇，等. 人乳头状瘤病毒DNA恒温扩增技术在宫颈癌筛查中的应用价值[J]. 中华肿瘤杂志，2018，40(4)：313-318. [4] 张柳红，陈煜岊，杨 岚，等. 人乳头状瘤病毒感染相关宫颈上皮内瘤变的治疗进展[J]. 国际流行病学传染病学杂志，2017，44(6)：416. [5] 毛 辉，叶敏欢. CO2激光联合ALA-PDT治疗男性尿道内尖锐湿疣的临床研究[J]. 中国性科学，2018，27(3)：78-80. [6] Zhai L，Hua C，Xiao Mei Z，et al.Expression and clinical significance of high risk human papillomavirus and invasive gene in cervical carcinoma[J].Asian Pacific Journal of Tropical Medicine，2017，2(10)：195-200. [7] 王 珍，贾赞慧，崔满华. 宫颈癌诊断新技术[J]. 中国妇幼保健，2018，33(4)：947-950. [8] 李晓林，袁文娟，陈 龙. 高危型HPV E6/E7 mRNA检测在宫颈机会性筛查中应用价值研究[J]. 中华肿瘤防治杂志，2017，24(4)：217-222. [9] Arkom C，Somchai N，Nakarin K，et al.Quantitative methylation analysis of human papillomavirus 16L1 gene reveals potential biomarker for cervical cancer progression[J].Diagnostic Microbiology and Infectious Disease.2017，4(89)：265-270. [10] 赵现立，高文丽，胡 彤. 宫颈上皮内瘤变合并高危型人乳头瘤病毒感染患者阴道感染研究[J]. 陕西医学杂志，2018，47 (8)：47-49. [11] 董丽花，徐永萍，范明华. 膦甲酸钠联合重组人干扰素α2b治疗宫颈HPV持续感染的疗效观察[J]. 中国药房，2017，28(2)：233-236.

更新日期/Last Update: 2019-07-12